Baldwin Wealth Partners LLC MA Sells 4,074 Shares of Veeva Systems Inc. $VEEV

Baldwin Wealth Partners LLC MA cut its holdings in Veeva Systems Inc. (NYSE:VEEV) by 14.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 24,813 shares of the technology company’s stock after selling 4,074 shares during the quarter. Baldwin Wealth Partners LLC MA’s holdings in Veeva Systems were worth $5,539,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Linden Thomas Advisory Services LLC increased its holdings in Veeva Systems by 0.3% in the third quarter. Linden Thomas Advisory Services LLC now owns 12,444 shares of the technology company’s stock valued at $3,707,000 after purchasing an additional 35 shares during the last quarter. Personal CFO Solutions LLC boosted its holdings in Veeva Systems by 3.5% during the third quarter. Personal CFO Solutions LLC now owns 1,163 shares of the technology company’s stock worth $346,000 after buying an additional 39 shares during the last quarter. AFT Forsyth & Company Inc. boosted its holdings in Veeva Systems by 4.2% during the third quarter. AFT Forsyth & Company Inc. now owns 984 shares of the technology company’s stock worth $293,000 after buying an additional 40 shares during the last quarter. Williams Jones Wealth Management LLC. grew its position in shares of Veeva Systems by 0.4% during the 3rd quarter. Williams Jones Wealth Management LLC. now owns 9,419 shares of the technology company’s stock worth $2,806,000 after buying an additional 40 shares during the period. Finally, Private Trust Co. NA grew its position in shares of Veeva Systems by 17.1% during the 3rd quarter. Private Trust Co. NA now owns 281 shares of the technology company’s stock worth $84,000 after buying an additional 41 shares during the period. Institutional investors and hedge funds own 88.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on VEEV. Morgan Stanley increased their price target on shares of Veeva Systems from $205.00 to $215.00 and gave the company an “equal weight” rating in a research report on Thursday, March 5th. UBS Group boosted their price objective on shares of Veeva Systems from $200.00 to $220.00 and gave the company a “neutral” rating in a report on Thursday, March 5th. Citigroup cut their target price on shares of Veeva Systems from $319.00 to $291.00 and set a “buy” rating on the stock in a report on Monday, March 9th. Weiss Ratings cut shares of Veeva Systems from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 12th. Finally, Wells Fargo & Company decreased their price target on shares of Veeva Systems from $333.00 to $317.00 and set an “overweight” rating for the company in a report on Thursday, March 5th. Seventeen investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $283.70.

Veeva Systems Price Performance

Shares of VEEV stock opened at $184.16 on Friday. The stock has a market cap of $30.27 billion, a P/E ratio of 34.04, a P/E/G ratio of 1.23 and a beta of 1.09. The company has a fifty day moving average price of $194.75 and a two-hundred day moving average price of $240.76. Veeva Systems Inc. has a one year low of $168.13 and a one year high of $310.50.

Veeva Systems (NYSE:VEEV) last issued its earnings results on Wednesday, March 4th. The technology company reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.94 by $0.12. Veeva Systems had a net margin of 28.44% and a return on equity of 14.11%. The business had revenue of $835.95 million during the quarter, compared to the consensus estimate of $810.95 million. During the same period last year, the business posted $1.74 EPS. Veeva Systems’s revenue was up 16.0% on a year-over-year basis. Veeva Systems has set its FY 2027 guidance at 8.850- EPS and its Q1 2027 guidance at 2.130-2.14 EPS. As a group, equities research analysts anticipate that Veeva Systems Inc. will post 4.35 EPS for the current fiscal year.

Veeva Systems announced that its Board of Directors has approved a stock repurchase program on Monday, January 5th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the technology company to reacquire up to 5.5% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board believes its stock is undervalued.

Insiders Place Their Bets

In other Veeva Systems news, insider Thomas D. Schwenger sold 1,000 shares of Veeva Systems stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $231.43, for a total transaction of $231,430.00. Following the completion of the transaction, the insider directly owned 23,204 shares of the company’s stock, valued at $5,370,101.72. The trade was a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 10.30% of the company’s stock.

Veeva Systems Profile

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.